Last update 01 Nov 2024

AGS8

Last update 01 Nov 2024

Basic Info

Synonyms

Activation-associated cDNA protein, AGS8, bA243O10.1

+ [8]

Introduction

May be an activator of G protein signaling.

Drugs associated with AGS8

CN117694546

Patent Mining

Target

AGS8

Mechanism-

Active Org.

Northwest A&F University

Originator Org.

Northwest A&F University

Active Indication

Developmental Disabilities

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

AGS-8M4

Target

AGS8

Mechanism

AGS8 inhibitors [+1]

Active Org.-

Originator Org.

Agensys, Inc.

Active Indication-

Inactive Indication

Carcinoma [+2]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

LSP-129

Target

AGS8

Mechanism

AGS8 inhibitors

Active Org.-

Originator Org.

Tokyo University of Science

Active Indication-

Inactive Indication

Hematologic Diseases [+1]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with AGS8

NCT01016054 / TerminatedPhase 1

A Phase 1b, Parallel Arm, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Two Different Chemotherapy Regimens in Women With Platinum Resistant or Platinum Sensitive Ovarian Cancer

This is a parallel arm study to evaluate AGS-8M4 administered in combination with chemotherapy in subjects with ovarian cancer. AGS-8M4 will be administered as an IV infusion until disease worsens.

Start Date01 Oct 2009

Sponsor / Collaborator

Astellas Pharma, Inc.

[+1]

NCT00816764 / CompletedPhase 1

A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-8M4 Given as Monotherapy in Subjects With Advanced Ovarian Cancer

This is the first in human study of AGS-8M4 given every 2 weeks to subjects with advanced ovarian cancer. AGS-8M4 will be administered as an IV infusion until the disease worsens.

Start Date01 Oct 2008

Sponsor / Collaborator

Astellas Pharma, Inc.

[+1]

100 Clinical Results associated with AGS8

100 Translational Medicine associated with AGS8

0 Patents (Medical) associated with AGS8

Literatures (Medical) associated with AGS8

11 Jun 2024·Open Life Sciences

Investigation into the association of FNDC1 and ADAMTS12 gene expression with plumage coloration in Muscovy ducks

Article

Author: Sun, Guo-Bo ; Duan, Xiu-Jun ; Lu, Yan-Feng

AbstractTo elucidate the molecular genetic mechanisms underpinning feather color in Muscovy ducks. A cohort of 100 Muscovy ducks was meticulously selected for this research. Follicular tissues from ducks exhibiting black and white plumage served as the experimental samples. From these tissues, RNA and proteins were extracted for further analysis. The RNA underwent reverse transcription polymerase chain reaction amplification, followed by validation through western blot assays. The data revealed a significant upregulation in the expression of FN domain-containing protein 1 (FNDC1) and ADAMTS12 genes in Muscovy ducks with white plumage traits as opposed to those with black plumage traits. Specifically, individuals with pure white plumage demonstrated a markedly elevated expression of the FNDC1 gene in comparison to their pure black counterparts. Conversely, expression levels of the ADAMTS12 gene were found to be reduced in ducks with pure black plumage relative to those with pure white plumage. Notably, the expression patterns of FNDC1 and ADAMTS12 genes exhibited inconsistencies between mRNA and protein levels. This study offers significant insights into the molecular genetic mechanisms underlying feather color variation in Muscovy ducks. FNDC1 and ADAMTS12 could be considered potential targets for genetic manipulation or selective breeding strategies aimed at achieving specific feather color phenotypes in Muscovy ducks.

01 Jan 2024·Frontiers in oncology

Retraction: FNDC1 promotes the invasiveness of gastric cancer via Wnt/β-catenin signaling pathway and correlates with peritoneal metastasis and prognosis.

[This retracts the article DOI: 10.3389/fonc.2020.590492.].

01 Sep 2023·iScience

Inhibition of FNDC1 suppresses gastric cancer progression by interfering with Gβγ-VEGFR2 complex formation

Article

Author: Lu, Yao ; Li, Jing ; Zhao, Rui ; Zeng, Xueliang ; Huang, Panpan ; Liu, Wenyu ; Tang, Xuerui ; Huang, Weicai ; Hu, Yaqiong ; Wu, Meng ; Xiao, Qiuxiang ; Wei, Hulai ; Cao, Gaolu ; Liu, Xiaojian

Gastric cancer (GC) is a prevalent digestive tract malignant tumor characterized by an insidious onset, ease of metastasis, rapid growth, and poor prognosis. Here, we report that fibronectin type III domain containing 1 (FNDC1) has high expression in GC and indicates poor outcomes in patients with GC. FNDC1 over-expression or knockdown promotes or inhibits tumorigenesis and metastasis, respectively. The expression of FNDC1 is upregulated by TWIST1, strengthening its interaction with Gβγ and VEGFR2. The formation of the trimers, TWIST1 plus Gβγ and VEGFR2, increases VEGFR2 phosphorylation and Gβγ trafficking, which activates RAS-MAPK and PI3K-AKT signaling, benefiting GC progression. In this study, we demonstrated that arsenite can efficiently suppress FNDC1 expression, attenuating the formation of the trimers and downstream pathways. Altogether, our results indicate that FNDC1 might be a promising target for clinical treatment and prognostic judgment, while FNDC1 inhibition by arsenite provides a new opportunity for overcoming this fatal disease.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

AGS8

Basic Info

Related

Analysis